Why I Can't Stop Buying AbbVie Stock [Yahoo! Finance]
Abbott Laboratories (ABT)
Last abbott laboratories earnings: 4/16 07:30 am
Check Earnings Report
US:NYSE Investor Relations:
abbott.com/investors.html
Company Research
Source: Yahoo! Finance
Skyrizi and Rinvoq replacing Humira faster than expected, driving immunology segment 18.3% growth in Q4. The analyst who called NVIDIA in 2010 just named his top 10 AI stocks. Get them here FREE AbbVie NYSE:ABBV ) has attracted persistent buying interest, and every pullback has drawn in value-focused investors. The stock is down 7.03% year-to-date as of mid-April 2026, sitting at $208.99, and it represents a level some analysts view as an opportunity. Here are three reasons the bull case remains compelling. Reason 1: The Dividend Machine Keeps Paying Investors to Wait AbbVie is a Dividend King with a proven track record. The quarterly dividend has risen every year since the company's 2013 spin-off from Abbott Laboratories, climbing from $0.40 per quarter in 2013 to $1.73 per quarter today. That most recent raise, announced in Q3 2025, was a 5.5% increase from $1.64. The annual dividend now stands at $6.65 per share, delivering a 3.19% yield at current prices. AbbVie pays sh
Show less
Read more
Impact Snapshot
Event Time:
ABT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABT alerts
High impacting Abbott Laboratories news events
Weekly update
A roundup of the hottest topics
ABT
News
- Abbott Laboratories (ABT) had its price target lowered by Barclays PLC from $144.00 to $143.00. They now have an "overweight" rating on the stock.MarketBeat
- Has the Abbott Laboratories Sell-Off Finally Created an Entry Point? [Yahoo! Finance]Yahoo! Finance
- Abbott Stock Crash: Rebound Could Be Coming Fast [Yahoo! Finance]Yahoo! Finance
- New data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection Test [Yahoo! Finance]Yahoo! Finance
- New data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection Test [TheStreet.com]TheStreet.com
ABT
Earnings
- 4/16/26 - Beat
ABT
Sec Filings
- 4/17/26 - Form 8-K
- 4/16/26 - Form 8-K
- 4/2/26 - Form 4
- ABT's page on the SEC website